Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Summary: The optimal duration of oral anticoagulant therapy for patients with acute proximal deep vein thrombosis (DVT) is uncertain. Based on the hypothesis that a normal impedance plethysmogram (IPG) following DVT defines a group of patients at low risk of recurrent venous thromboembolism (VTE), a trial was conducted to evaluate the efficacy of only four weeks of warfarin. Patients with venographically confirmed acute proximal DVT who had received four weeks of warfarin after initial heparin and whose four week IPG was normal were allocated to either continue warfarin (targeted International Normalized Ratio 2.0 to 3.0) for a further eight weeks or receive placebo. Patients with an abnormal four week IPG received warfarin for a further eight weeks. Based on clinical characteristics at the time of the qualifying thrombosis, all patients were classified as having either continuing or transient risk factors for recurrent VTE. During the eight weeks following randomization, nine (8.6%) of the 105 placebo patients developed recurrent VTE compared to one (0.9%) of the 109 warfarin patients, P = 0.009. Over the entire 11 months of follow-up, 12 placebo patients developed recurrence compared to seven warfarin patients, P = 0.3. Nineteen of the 192 patients with an abnormal four week IPG experienced recurrence during the nine months after discontinuing warfarin. In the 301 patients who received three months of warfarin in the randomized trial or in the cohort study, all 26 recurrent events were in the 212 patients with continuing risk factors. In conclusion, an IPG four weeks after proximal DVT is not a useful predictor for recurrent VTE; whereas the presence of continuing risk factors is a very strong predictor. Four weeks of oral anticoagulants may be all that is required in patients without continuing risk factors. Patients with continuing risk factors may require more than three months of oral anticoagulants.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies have demonstrated that primary treatment should continue for a minimum of 3 to 6 months for all patients with VTE. 235,236”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [236]
Citations
Cites
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Antithrombotic Therapy for Venous Thromboembolic Disease
Hyers, T. M., Agnelli, G., Hull, R. D., Morris, T. A., Samama, M., Tapson, V., & Weg, J. G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.176s · Cited by 2,042
Detection of Deep-Vein Thrombosis by Real-Time B-Mode Ultrasonography
Lensing, A. W. A., Prandoni, P., Brandjes, D., Huisman, P. M., Vigo, M., Tomasella, G., Krekt, J., ten Cate, J. W., Huisman, M. V., & Büller, H. R. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902093200602 · Cited by 875
Different Intensities of Oral Anticoagulant Therapy in the Treatment of Proximal-Vein Thrombosis
Hull, R., Hirsh, J., Jay, R., Carter, C., England, C., Gent, M., Turpie, A. G. G., McLoughlin, D., Dodd, P., Thomas, M., et al. (1982) · New England Journal of Medicine · doi:10.1056/nejm198212303072704 · Cited by 728
Self-citationHull, R. D., Raskob, G. E., Hirsh, J., Jay, R. M., Leclerc, J. R., Geerts, W. H., Rosenbloom, D., Sackett, D. L., Anderson, C., Harrison, L., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610303151801 · Cited by 722
Self-citationHull, R. D., Raskob, G. E., Pineo, G. F., Green, D., Trowbridge, A. A., Elliott, C. G., Lerner, R. G., Hall, J., Sparling, T., Brettell, H. R., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199204093261502 · Cited by 700
HULL, R. D., HIRSH, J., CARTER, C. J., JAY, R. M., DODD, P. E., OCKELFORD, P. A., COATES, G., GILL, G. J., TURPIE, A. G., DOYLE, D. J., et al. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-6-891 · Cited by 645
Self-citationWarfarin Sodium versus Low-Dose Heparin in the Long-Term Treatment of Venous Thrombosis
Hull, R., Delmore, T., Genton, E., Hirsh, J., Gent, M., Sackett, D., McLoughlin, D., & Armstrong, P. (1979) · New England Journal of Medicine · doi:10.1056/nejm197910183011602 · Cited by 604 · cited 2×
“received three months of warfarin in a series of randomized clinical trials (3-5).”
BackgroundSelf-citationPrandoni, P., Carta, M., Cogo, A., Ruol, A., Vigo, M., Casara, D., Lensing, A. W. A., Büller, H. R., & ten Cate, J. W. (1992) · The Lancet · doi:10.1016/0140-6736(92)91054-c · Cited by 583
Adjusted Subcutaneous Heparin versus Warfarin Sodium in the Long-Term Treatment of Venous Thrombosis
Hull, R., Delmore, T., Carter, C., Hirsh, J., Genton, E., Gent, M., Turpie, G., & McLaughlin, D. (1982) · New England Journal of Medicine · doi:10.1056/nejm198201283060401 · Cited by 436
Self-citation
Cited by
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism
Authors/Task Force Members, Konstantinides, S. V., Torbicki, A., Agnelli, G., Danchin, N., Fitzmaurice, D., Galiè, N., Gibbs, J. S. R., Huisman, M. V., Humbert, M., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu283 · Cited by 3,128
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Jaff, M. R., McMurtry, M. S., Archer, S. L., Cushman, M., Goldenberg, N., Goldhaber, S. Z., Jenkins, J. S., Kline, J. A., Michaels, A. D., Thistlethwaite, P., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318214914f · Cited by 2,229
Metadata
- Authors
- Levine, M. N., Hirsh, J., Gent, M., Turpie, A. G., Weitz, J., Ginsberg, J., Geerts, W., LeClerc, J., Neemeh, J., Powers, P., & Piovella, F.
- Affiliations
- McMaster University (CA)
- Venue
- Thrombosis and Haemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 1995
- Volume
- 74
- Issue
- 02
- Pages
- 606-611
- ISSN
- 0340-6245 (ISSN-L)
- 2567-689X
- OpenAlex
- W55954674
- Cited by
- 353
- References
- 19
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 4 · 2021: 4 · 2020: 6 · 2019: 2 · 2018: 9 · 2017: 9 · 2016: 5 · 2015: 10 · 2014: 16 · 2013: 7 · 2012: 12
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Thrombosis and Haemostasis (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Clinical Neurology › Cerebral Venous Sinus Thrombosis
- Keywords
- proximal deep vein thrombosis, warfarin, venous thromboembolism recurrence, impedance plethysmography, recurrence risk factors, heparin, anticoagulation discontinuation
- MeSH terms
- Adult, Aged, Anticoagulants, Double-Blind Method, Drug Administration Schedule, Female, Follow-Up Studies, Heparin, Humans, Male, Middle Aged, Plethysmography, Impedance, Recurrence, Risk Factors, Thrombophlebitis, Time Factors, Warfarin, Cohort Studies, Incidence, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis. https://app.cochat.ai/papers/10.1055/s-0038-1649783
- The paper
- Levine, M. N., Hirsh, J., Gent, M., Turpie, A. G., Weitz, J., Ginsberg, J., Geerts, W., LeClerc, J., Neemeh, J., Powers, P., & Piovella, F. (1995). Optimal Duration of Oral Anticoagulant Therapy: A Randomized Trial Comparing Four Weeks with Three Months of Warfarin in Patients with Proximal Deep Vein Thrombosis. Thrombosis and Haemostasis. https://doi.org/10.1055/s-0038-1649783
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.